COMMUNIQUÉS West-GlobeNewswire

Telix Announces Collaborations to Explore PSMA-PET Imaging in Emerging Prostate Cancer Treatment Approaches
15/05/2026
Telix to partner with companies developing advanced minimally invasive and image-guided ablative technologies for prostate cancer. Initial focus on patient selection, treatment planning and post-treatment monitoring; [...]
Positive Interim Data from Cohorts 1 and 2 of Tenaya’s RIDGE™-1 Phase 1b/2 Clinical Trial of TN-401 Demonstrated Consistent Reductions in Arrhythmia Burden for Adults with PKP2-associated ARVC
15/05/2026
All Patients Achieved Meaningful Decreases (Mean = 64%) in Daily Premature Ventricular Contraction Count TN-401 Gene Therapy was Well Tolerated at 3E13 vg/kg and 6E13 vg/kg Doses Post-dose Biopsies Provide Evidence of [...]
ARS Pharmaceuticals Reports First Quarter 2026 Financial Results and Corporate Update
15/05/2026
Q1 2026 total revenue of $22.7 million including neffy ® (epinephrine nasal spray) U.S. net product revenue of $17.5 million CVS Caremark proposal in final stages of approval process; definitive update anticipated in [...]
Initiation of buy-back programme
15/05/2026
ANNOUNCEMENT NO. 309 15 May 2026 Initiation of buy-back programme The Board of Directors of ChemoMetec A/S has decided to buy back own shares based on the authorisation granted at the Annual General Meeting on 9 October [...]
105,950 Orion Corporation A shares converted into B shares
15/05/2026
ORION CORPORATION STOCK EXCHANGE RELEASE – OTHER INFORMATION DISCLOSED ACCORDING TO THE RULES OF THE EXCHANGE 15 MAY 2026 at 9.00 EEST 105,950 Orion Corporation A shares converted into B shares In accordance with [...]
Desert Hope Treatment Center Welcomes Alumni Coordinator Whose Recovery Journey Began in Its Program
15/05/2026
LAS VEGAS, May 14, 2026 (GLOBE NEWSWIRE) -- Desert Hope Treatment Center, a leading addiction treatment center in Las Vegas, has appointed Madot (“Maddie”) Gebreegziabher as Alumni Coordinator. In her role, Maddie leads [...]
Fortress Biotech Reports First Quarter 2026 Financial Results and Recent Corporate Highlights
14/05/2026
ZYCUBO ® approved by FDA to treat Menkes disease in the United States; Fortress subsidiary Cyprium Therapeutics closed the sale of its Rare Pediatric Disease Priority Review Voucher (PRV) for $205 million Fortress’ [...]
Calidi Biotherapeutics Reports First Quarter 2026 Financial Results and Recent Operational Highlights
14/05/2026
Presented new data on CLD-401 at the AACR conference in San Diego, CA, detailing the profound immune changes in the tumor microenvironment induced by CLD-401; IND filing for CLD-401 expected by end of 2026 Presented new [...]
Cardiff Oncology Reports First Quarter 2026 Results and Provides Business Update
14/05/2026
Completed successful End-of-Phase 2 meeting with the FDA and selected onvansertib dose and chemotherapy regimen for planned Phase 3 trial Company to provide detailed data update from Phase 2 CRDF-004 trial in rapid oral [...]
BIO GREEN MED SOLUTION REPORTS FIRST QUARTER FINANCIAL RESULTS AND PROVIDES BUSINESS UPDATE
14/05/2026
KUALA LUMPUR, MALAYSIA, May 14, 2026 (GLOBE NEWSWIRE) -- Bio Green Med Solution, Inc. (NASDAQ: BGMS; “BGMS” or the “Company”), a diversified company engaged primarily in the provision of fire safety protection and [...]
First Tracks Biotherapeutics Announces First Quarter 2026 Financial Results and Provides Business Update
14/05/2026
First Tracks launched April 20 th with a two-year cash-runway to advance ANB033 through celiac disease and eosinophilic esophagitis Phase 1b data and plans to initiate Phase 2 trials across four indications SAN DIEGO, [...]
Tempest Reports First Quarter 2026 Financial Results and Provides Business Update
14/05/2026
Announced positive interim data from the ongoing REDEEM-1 Phase 1/2a trial of TPST-2003 in patients with relapsed/refractory multiple myeloma (rrMM) Announced Cincinnati Children’s Applied Gene and Cell Therapy Center [...]
Serina Therapeutics Reports First Quarter 2026 Financial Results and Provides Business Updates
14/05/2026
Phase 1b Registrational Clinical Study of SER-252 Underway in Advanced Parkinson’s Disease; TFL data from the SAD study arm targeted for first half of 2027 - – Closed $21.2 million private placement financing to support [...]
HCW Biologics Reports First Quarter 2026 Business Highlights and Financial Results
14/05/2026
MIRAMAR, Fla., May 14, 2026 (GLOBE NEWSWIRE) -- HCW Biologics Inc. (the “Company” or “HCW Biologics”) (NASDAQ: HCWB), a clinical-stage biopharmaceutical company focused on developing transformative fusion [...]
Ocugen, Inc. Announces Closing for $130.0 Million of 6.75% Convertible Senior Notes
14/05/2026
Includes Full Exercise of $15.0 million Over-Allotment Option MALVERN, Pa., May 14, 2026 (GLOBE NEWSWIRE) -- Ocugen, Inc. (Ocugen or the Company) (NASDAQ: OCGN), a pioneering biotechnology leader in gene therapies for [...]
Medicus Pharma Reports First Quarter 2026 Financial Results and Provides Corporate Update
14/05/2026
Company Advances SkinJect® and Teverelix® Clinical Programs While Strengthening Financing Flexibility and Expanding Strategic Development Initiatives PHILADELPHIA, May 14, 2026 (GLOBE NEWSWIRE) -- Medicus Pharma Ltd. ( [...]
Solésence Supports Landmark Report on UV Safety in the United Kingdom as Member of UV Safety Coalition
15/05/2026
The report, led by the United Kingdom’s APPG for Beauty, Hair & Wellbeing, calls for a national strategy to combat UV exposure, including Government support to enable access to adequate protection, build public [...]
Glucotrack Reports First Quarter 2026 Financial Results and Recent Corporate Highlights
14/05/2026
Submitted Investigational Device Exemption (IDE) application to the U.S. Food and Drug Administration (FDA) to initiate a U.S. clinical study for fully implantable continuous blood glucose monitoring (CBGM) technology [...]
BioSyent Releases Financial Results for First Quarter 2026
15/05/2026
MISSISSAUGA, Ontario, May 14, 2026 (GLOBE NEWSWIRE) -- BioSyent Inc. (“BioSyent”, TSX Venture: RX) released today its financial results for the first quarter (Q1) ended March 31, 2026. Key highlights include: (CAD) Q1 [...]

Pages